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ABSTRACT
Metastasis is a complex and well-coordinated phenotypic transformation of cancer cells governed by aberrant genetic and molecular pathways. It has been approved as the most consistent cause of cancer death.
With emerging insight into the genomics, transcriptomics and proteomics, progress has been made and
reasonably large number of molecular pathways of metastasis has been forwarded, but our understanding
of precise underlying molecular mechanisms remains largely scarce. It has been well-known for around a
decade and more that platelets are intriguingly contributing to the cancer metastasis. However, it is only
recently that cancer cells can activate platelets have started to become apparent. Surprisingly, platelets in
response to cancer cell activation, supported by research observations, allow cancer cells to escape immune
removal, prolong survival in vascular compartment, increased cellular adhesion and develop new cellular
niches which eventually help to favor cancer metastasis. Although a widely acknowledged plausible explanation that cancer cells activate platelets to facilitate in their distant spread, the description of this remains
to be confirmed. In recent years, mucins, heavily glycosylated peptide structure, have been introduced to
be released by several types of cancer cells. They account for poor prognosis in wide array of malignancies, because of their significant ability to induce metastatic process. The mechanism responsible for their
increased metastatic propensity remains uncharacterized, but recent work suggested the role of cancer
expressed mucins in initiating platelet thrombus. The association of cancer yield mucins, platelets and metastasis therefore suggests a pressing need to explore novel molecular mechanisms and therapeutic targets
thereafter.

Cancer is an umbrella term used to designate a number of diseases originating from oncogenic tissues that overcome the normal
cellular mechanisms by overexpressing self-renewal and resisting
growth inhibiting and death promoting signals. Cancer is recognized as a chronic, non-healing wound that strikes millions of
lives around the globe.[1] Based on the WHO cancer statistics,
approximately 14.1 million newly diagnosed cases and 8.2 million
deaths were accounted to cancer in 2012. Further, the incidence
of cancer is gauged to rise exponentially by 70% over upcoming
two decades.[2] The globalization of cancer is prominently the
consequence of adopting cancer-enriching, modernized lifestyle
patterns such as substance abuse (smoking and alcohol use), cessation of physical activity and unhealthy dietary habits (low fruit
and vegetable intake).[3] The impact of cancer extends beyond
the physical and psychological realms with significant financial
consequences. In addition, it enormously influences the quality of
life (QoL); as a consequence the behavior of cancer patients and
their family member’s decisions with regard to their treatment.

[4, 5]
Metastasis entails a complex cascade of cellular and molecular events that mediate cancer cells to circulate and form secondary niche within distant tissue systems through ongoing bidirectional interaction with the host microenvironment in a manner
that is conducive to survival and proliferation of cancer cells.
[6] The expression of necessary characteristics such as genetic
and epigenetic instability, presence of cancer stem cells, immunoevasive self-defenses, positive interaction with foreign (host)
microenvironments, sustained cell cycles and chemotherapeutic
antagonism sets in motion the lethal phenotypic facet of cancer;
metastasis.[7, 8] Metastasis contributes to nearly 90% of cancer
related deaths.[9] Patients who are diagnosed with cancers that
are metastatic at presentation tend to have poor outcomes; an improved understanding of this phenomenon might provide an additional prognostic marker. Furthermore, the poor outcomes for
these patients emphasize the importance of deciphering biological
pathways contributing to metastasis as a means for developing
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novel anti-metastatic therapies. Nonetheless, the underlying
molecular mechanisms governing these interactions are yet to be
deciphered.
Since the discovery of Trousseau's syndrome in 1865, platelets have been extensively trialed for their potential in advancing
cancer through metastasis.[10] Platelets, besides their established
role in hemostasis and thrombosis, facilitate tumor invasiveness
upon activation. The reciprocity of cancer cells and platelets is
critical for development of cancer metastasis. Review studies
supports the published evidence that thrombocytosis is directly
proportional to the increased propensity of cancer cells to express metastatic behavior and poor prognosis and life expectancy
among cancer patients.[11] Studies have also documented that
formation of ‘platelet cloak’ around cancer cells to evade immune
cell cytotoxic lysis is at the mercy of activated platelets. Additionally, platelet releasates carry diverse vasogenic, mitogenic and
chemotactic factors that nurture the tumor growth and support
metastasis.[12] Likewise, platelets have also been implicated to
gather leukocytes through chemical signals at the site of plateletcancer cell interaction, thereby mediating smooth survival of
tumor in vascular compartment and penetration to distant organs.
[13]
Mucins, biochemically, are abundantly glycosylated proteins
of high molecular weight with defining feature of serine and
threonine amino acid tandem repeats.[14] The promising physiological functions of mucins such as cellular differentiation, cellular adhesion, cellular signaling and immune regulation make
them an important part of proteomics research.[15] Conversely,
their deviant expression in diseased states including inflammatory
and cancerous conditions has been well reported on several occasions.[16-18] Mucins expressing human carcinomas are prone to
increased metastasis and foreshadow poor clinical outcomes.[19]
With the major breakthrough in molecular attributes of cancer,
mucins and their association with platelet activation and cancer
metastasis has assembled a lot of awareness over past few years.
Cancer cells expressing abnormal cell surface molecules,
specifically the altered mucin glycoproteins are remarkable for
their interaction with E, L and P-selectins. Notably, selectins also
carry the potential to recognize and bind the altered carbohydrate
molecules expressed by cancer cells. Certainly, such associations
allow cancer cells to interact with blood borne cells including
endothelial cells, leukocytes and platelets and mediate their aggressive metastatic phenotype.[20-22] Previous studies have attempted to ascertain the link between the trio of mucin, platelets
and metastasis.
Platelets can be activated by mucins in a selectin-dependent
manner, emphasizing the importance of mucin-selectin interaction, P and L-selectins in particular. The proposed mechanism of
platelet activation by mucin is indirect and facilitated by leukocytes via interaction with L-selectin. P-selectins and their role in
cancer metastasis have been the subject of extensive research over
the last few years with P-selectin expression demonstrated in activated platelets.[23, 24] Furthermore, the ability of P-selectins to
aggregate platelets cannot be underestimated.[25-27] A literature
review suggested both in vivo and in vitro interaction of platelets
with cancer derived mucins reliant on P-selectin availability. In
addition, the platelet-mucin interaction without external thrombin utilization is supported by in vivo observation. Experimental
removal of mucin from cancer cell lines significantly reduces
the strength of metastasis and studies have demonstrated that
tumor cell-platelet aggregation as well as establishment of tumor metastasis was attenuated in P-selectin-deficient mice.[28]
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This demonstrates the crucial role of hidden molecular pathways
harmonized by cancer derived mucins to augment the metastatic
process. Despite these exciting strides made over the last two
decades, the precise mechanism of mucin platelet interaction and
their role in cancer metastasis remains to be ascertained.

1. Conclusion
Taken together, metastasis still represents the major cause of
cancer related mortality. Unfortunately, the concealed molecular
pathways guiding the primary tumors to invade distant organs
remain to be elucidated. Mucin, until recently, is emerging as a
new accessory source for cancer to unfurl their metastatic terror.
Screening of tumor with metastatic constitution is a growing concern and demands aggressive measures to attenuate its negative
prognostic impact on active cases. On this account, experimental
analysis will be of immense value to identify the intensity and
precision of mucin contribution towards metastasis and its sensitivity and specificity both as prognostic and diagnostic molecular
marker. A step towards development of accurate and reliable relationship among mucin, platelets and metastasis will eventually
yield unprecedented new insights into the future therapy.
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